Maravai LifeSciences MRVI
$6.98 −$0.21 (-2.92%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.98 0.00%
Open$7.06
Prev close$7.19
Day range$6.91 – $7.17
Volume1.79M
Market cap$1.04B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$45.85M+10.1% YoY
Operating profit-$17.70M+47.4% YoY
Net profit-$24.00M+46.7% YoY
Diluted EPS-$0.09+50.0% YoY
Free cash flow$4.49M+124.9% YoY
Operating cash flow$5.02M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin39.1%
Operating margin-25.6%
Net margin-30.8%
Return on equity-29.8%
Return on assets-9.1%
Return on invested capital-10.3%
Current ratio4.66
Liabilities / assets43.3%
Cash & investments$73.02M
Total debt$176.48M
Net cash (debt)-$103.45M
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $45.85M | $51.44M | $65.84M | $185.74M | $49.87M |
| Total Operating Revenue | $45.85M | $51.44M | $65.84M | $185.74M | $49.87M |
| Cost of Revenue | $29.66M | $30.79M | $32.14M | $151.75M | $37.02M |
| Gross Profit | $16.19M | $20.65M | $33.70M | $33.99M | $12.84M |
| Operating Expense | $33.89M | $35.77M | $32.98M | $162.52M | $35.17M |
| Selling and Admin Expenses | $30.50M | $32.07M | $29.09M | $145.12M | $31.38M |
| Research & Development | $3.39M | $3.70M | $3.89M | $17.40M | $3.79M |
| Operating Profit | -$17.70M | -$15.12M | $720,000.00 | -$128.53M | -$22.33M |
| Net Non-Operating Interest Income (Expense) | -$3.43M | -$3.65M | -$3.88M | -$15.56M | -$4.17M |
| Non-Operating Interest Income | $598,000.00 | $1.16M | $1.87M | $11.44M | $2.38M |
| Non-Operating Interest Expense | $4.03M | $4.81M | $5.75M | $26.99M | $6.56M |
| Other Income (Expense) | -$2.95M | -$3.03M | -$3.37M | -$90.89M | -$36.51M |
| Special Income (Charges) | -$2.92M | -$2.98M | -$2.88M | -$86.74M | -$36.47M |
| -Less:Restructuring and Mergern & Acquisition | $2.92M | -$33,000.00 | $2.88M | $18.03M | $10.64M |
| -Less:Impairment of Capital Assets | $0.00 | $0.00 | $0.00 | $68.71M | $25.83M |
| Other Non-Operating Income (Expenses) | -$27,000.00 | -$52,000.00 | -$494,000.00 | -$4.15M | -$43,000.00 |
| Pretax Profit | -$24.08M | -$21.80M | -$6.53M | -$234.97M | -$63.01M |
| Tax | -$75,000.00 | -$171,000.00 | -$151,000.00 | -$4.21M | $6,000.00 |
| Net Profit | -$24.00M | -$21.63M | -$6.38M | -$230.76M | -$63.02M |
| Profit from Continuing Operations | -$24.00M | -$21.63M | -$6.38M | -$230.76M | -$63.02M |
| Minority Interests | -$10.16M | -$9.22M | -$2.64M | -$99.99M | -$27.33M |
| Net Income to Parent Company | -$13.84M | -$12.42M | -$3.73M | -$130.77M | -$35.68M |
| Net Income to Common Stockholders | -$13.84M | -$12.42M | -$3.73M | -$130.77M | -$35.68M |
| Basic EPS | -$0.09 | -$0.08 | -$0.02 | -$0.90 | -$0.24 |
| Diluted EPS | -$0.09 | -$0.08 | -$0.02 | -$0.90 | -$0.24 |
| -Less:Other Special Charges | – | $3.01M | – | – | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $600.07M | $603.75M | $713.22M | $770.58M | $770.58M |
| Total Current Assets | $154.00M | $155.66M | $251.74M | $296.25M | $296.25M |
| Cash and Cash Equivalents & Short-Term Investments | $73.02M | $70.09M | $165.92M | $216.89M | $216.89M |
| -Cash and Cash Equivalents | $73.02M | $70.09M | $165.92M | $216.89M | $216.89M |
| Receivables | $25.71M | $31.14M | $33.42M | $25.50M | $25.50M |
| -Accounts Receivable | $25.71M | $31.14M | $33.42M | $25.50M | $25.50M |
| Inventory | $43.25M | $41.23M | $40.46M | $40.50M | $40.50M |
| Other Current Assets | $12.02M | $13.20M | $11.94M | $13.37M | $13.37M |
| Total Non-Current Assets | $446.07M | $448.09M | $461.48M | $474.33M | $474.33M |
| Net PPE | $135.67M | $142.41M | $146.93M | $190.74M | $190.74M |
| -Gross PPE | $135.67M | $142.41M | $146.93M | $258.82M | $258.82M |
| Goodwill and Other Intangible Assets | $260.40M | $267.80M | $274.32M | $280.97M | $280.97M |
| -Goodwill | $129.43M | $129.43M | $129.43M | $129.43M | $129.43M |
| -Other Intangible Assets | $130.97M | $138.38M | $144.89M | $151.54M | $151.54M |
| Other Non-Current Assets | $50.00M | $37.87M | $40.24M | $2.62M | $2.62M |
| Total Liabilities | $259.90M | $248.16M | $344.13M | $397.87M | $397.87M |
| Total Current Liabilities | $33.06M | $38.42M | $42.62M | $44.92M | $44.92M |
| Payables | $6.48M | $7.13M | $8.54M | $3.65M | $3.65M |
| -Accounts Payable | $6.48M | $7.13M | $8.54M | $2.91M | $2.91M |
| Current Accrued Expenses | $25.08M | $30.17M | $28.65M | $11.08M | $11.08M |
| Short-Term Debt and Capital Lease Obligation | $1.50M | $1.13M | $5.44M | $14.20M | $14.20M |
| -Current Debt | $1.50M | $1.13M | $5.44M | $5.44M | $5.44M |
| Total Non-Current Liabilities | $226.84M | $209.74M | $301.51M | $352.95M | $352.95M |
| Long Term Debt and Capital Lease Obligation | $174.98M | $175.57M | $265.44M | $350.51M | $350.51M |
| -Long Term Debt | $145.68M | $145.98M | $235.57M | $286.33M | $286.33M |
| -Long Term Capital Lease Obligation | $29.30M | $29.59M | $29.87M | $64.18M | $64.18M |
| Other Non-Current Liabilities | $51.86M | $34.17M | $36.07M | $197,000.00 | $197,000.00 |
| Total Equity | $340.17M | $355.59M | $369.08M | $372.71M | $372.71M |
| Stockholders' Equity | $195.89M | $204.62M | $211.56M | $212.38M | $212.38M |
| Capital Stock | $2.60M | $2.60M | $2.58M | $2.56M | $2.56M |
| -Common Stock | $2.60M | $2.60M | $2.58M | $2.56M | $2.56M |
| Additional Paid-In Capital | $212.70M | $207.60M | $202.13M | $199.18M | $199.18M |
| Retained Earnings | -$19.87M | -$6.03M | $6.39M | $10.12M | $10.12M |
| Gains/Losses Not Affecting Retained Earnings | $456,000.00 | $459,000.00 | $466,000.00 | $524,000.00 | $524,000.00 |
| Minority Interests | $144.28M | $150.97M | $157.52M | $160.33M | $160.33M |
| -Accumulated Depreciation | – | – | – | -$68.08M | -$68.08M |
| -Total Tax Payable | – | – | – | $742,000.00 | $742,000.00 |
| -Current Capital Lease Obligation | – | – | – | $8.76M | $8.76M |
| Current Deferred Liabilities | – | – | – | $2.99M | $2.99M |
| Other Current Liabilities | – | – | – | $1.89M | $1.89M |
| Long Term Accounts Payable and Other Payables | – | – | – | $0.00 | $0.00 |
| Non-Current Accrued Expenses | – | – | – | $0.00 | $0.00 |
| Non-Current Deferred Liabilities | – | – | – | $2.25M | $2.25M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | $5.02M | $3.99M | $8.67M | -$57.57M | -$22.77M |
| Net cash flow from continuing operations | $5.02M | $3.99M | $8.67M | -$57.57M | -$22.77M |
| Net Income from Continuing Operations | -$24.00M | -$21.63M | -$6.38M | -$230.76M | -$63.02M |
| Gain/Loss from Continuing Operations | $0.00 | – | – | – | – |
| Depreciation & Depletion & Amortization | $13.85M | $13.41M | $12.98M | $60.47M | $14.73M |
| Deferred Tax | $0.00 | – | – | $4.06M | -$20,000.00 |
| Other Non-Cash Items | $51,000.00 | -$340,000.00 | $541,000.00 | $1.87M | $657,000.00 |
| Change in Working Capital | $2.96M | -$926,000.00 | -$5.83M | -$7.98M | -$19.43M |
| -Change in Receivables | $5.44M | $2.29M | -$7.91M | $12.82M | -$2.96M |
| -Change in Inventory | -$2.02M | -$768,000.00 | $33,000.00 | $8.00M | $3.09M |
| -Change in Prepaid Assets | $1.18M | -$771,000.00 | $1.43M | $1.63M | $1.18M |
| -Change in Payables and Accrued Expense | -$5.54M | $15,000.00 | $826,000.00 | -$11.97M | -$19.03M |
| -Change in Other Current Liabilities | $3.90M | -$1.69M | -$203,000.00 | -$18.63M | -$1.89M |
| Net cash flow from investing | -$523,000.00 | -$370,000.00 | -$4.44M | -$31.41M | -$2.11M |
| Net Cash Flow from Continuing Investing Activities | -$523,000.00 | -$370,000.00 | -$4.44M | -$31.41M | -$2.11M |
| Net PPE Purchase and Sale | -$523,000.00 | -$370,000.00 | -$4.44M | -$12.42M | -$2.11M |
| Net Business Purchase and Sale | $0.00 | $0.00 | $0.00 | -$18.99M | $0.00 |
| Financing Cash Flow | -$1.57M | -$98.98M | -$55.23M | -$16.50M | -$1.82M |
| Net Cash Flow from Continuing Financing Activities | -$1.57M | -$98.98M | -$55.23M | -$16.50M | -$1.82M |
| Net Issuance Payments Of Debt | $0.00 | -$92.88M | -$51.36M | -$5.44M | -$1.36M |
| Proceeds from Stock Option Exercised | -$1.33M | – | – | – | – |
| Net Other Financing Charges | -$244,000.00 | -$164,000.00 | -$3.87M | -$11.06M | -$5.06M |
| Ending Cash Balance | $73.51M | $70.58M | $165.92M | $216.89M | $216.89M |
| Net Change in Cash | $2.92M | -$95.36M | -$51.00M | -$105.48M | -$26.70M |
| Beginning Cash Balance | $70.58M | $165.92M | $216.89M | $322.40M | $243.57M |
| Effect of Exchange Rate Changes | $10,000.00 | $17,000.00 | $30,000.00 | -$32,000.00 | $14,000.00 |
| Free Cash Flow | $4.49M | $3.62M | $4.23M | -$70.72M | -$25.62M |
| -Change in Other Current Assets | – | – | – | $181,000.00 | – |
No comments yet — be the first to weigh in on MRVI.
Sign in to join the discussion.